UK Markets close in 25 mins

Altimmune, Inc. (0A4C.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
4.8100-0.4800 (-9.07%)
As of 03:36PM BST. Market open.

Altimmune, Inc.

910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240 654 1450

Full-time employees47

Key executives

NameTitlePayExercisedYear born
Dr. Vipin K. Garg Ph.D.Pres, CEO & Director869.46kN/A1958
Mr. Richard I. Eisenstadt M.B.A.Chief Financial Officer120kN/A1958
Dr. M. Scot Roberts Ph.D.Chief Scientific Officer564.87kN/A1959
Dr. Matthew Scott Harris AGAF, FCAP, M.D., MSChief Medical Officer614.11kN/A1953
Mr. Bertrand Georges Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. José OchoaChief Bus. OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Corporate governance

Altimmune, Inc.’s ISS governance QualityScore as of 1 May 2022 is 9. The pillar scores are Audit: 8; Board: 7; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.